Salta al menu principale di navigazione Salta al contenuto principale Salta al piè di pagina del sito
FrancoAngeli Journals

Contributi Scientifici

N. 75 (2026)

Nuove frontiere nutraceutiche nel recupero dalle dipendenze

DOI
https://doi.org/10.3280/mis75-2026oa23672
Inviata
8 settembre 2026
Pubblicato
08-10-2026

Abstract

The evolution of addiction neurobiology highlights the limitations of conventional acute-phase pharmacological treatments in preventing long-term relapse. Chronic substance abuse triggers severe metabolic breakdown, neuroinfl ammation, mitochondrial dysfunction, and oxidative stress within the central nervous system, impairing the homeostasis of the glutamatergic system. This neuroprogressive state compromises prefrontal executive control, exacerbating craving and vulnerability to stress-induced relapse. Addressing this underlying biological deficit requires innovative therapeutic strategies aimed at restoring cellular homeostasis and neural plasticity.
In this context, the complementary nutraceutical approach using N-acetylcysteine (NAC) and alpha-lipoic acid (ALA) represents a promising adjuvant intervention. NAC acts by restoring astrocytic glutamate homeostasis via the xCT exchanger and enhancing intracellular glutathione synthesis, thereby attenuating cueinduced craving. Concurrently, ALA supports mitochondrial bioenergetics, activates the Nrf2 antioxidant response pathway, and recycles endogenous antioxidants. Together, NAC and ALA offer a synergistic mechanism to mitigate neurotoxicity, alleviate neuroinflammation, and preserve cognitive function, providing a rationale-driven framework for relapse prevention and long-term neurocognitive rehabilitation.

Riferimenti bibliografici

  1. Aguirre N., Barrionuevo M., Ramírez M.J., Del Río J., & Lasheras B. (1999). Alpha-lipoic acid prevents 3,4-ethylenedioxymethamphetamine
  2. (MDMA)-induced neurotoxicity. Neuroreport, 10(17): 3675-80.
  3. Amen S.L. et al. (2011). Repeated N-acetyl cysteine reduces cocaine seeking in rodents and craving in cocaine-dependent humans. Neuropsychopharmacology, 36(4): 871-8.
  4. Aoyama K., Watabe M., & Nakaki T. (2008). Regulation of neuronal glutathione synthesis. Journal of Pharmacological Sciences, 108(3): 227-38.
  5. Arias-Carrión O. et al. (2026). Multisystem regulation of reward and addiction: beyond the dopaminergic system. Frontiers in Pharmacology, 17, 1840096.
  6. Cancela L.M., Mongi-Bragato B., Avalos M.P., & Bollati F.A. (2025). From stress to substance use disorders: The expanding role of microglia-astrocyte crosstalk in neuroimmune and glutamate alterations in the nucleus accumbens. International Journal of Molecular Sciences, 27(1): 385.
  7. Cheron J., & Kerchove d’Exaerde A. (2021). Drug addiction: from bench to bedside. Translational Psychiatry, 11(1): 424.
  8. Crews F.T., Lawrimore C.J., Walter T.J., & Coleman L.G. Jr. (2017). The role of neuroimmune signaling in alcoholism. Neuropharmacology, 122: 56-73.
  9. Cuocina M. et al. (2024). Effect of N-acetylcysteine on craving in substance use disorders (SUD): a meta-analysis of randomized controlled trials. Frontiers in Pharmacology, 15, 1462612.
  10. da Silva M.C.M. et al. (2023). Role of microglia in psychostimulant addiction. Current Neuropharmacology, 21(2): 235-259.
  11. Deepmala et al. (2015). Clinical trials of N-acetylcysteine in psychiatry and neurology: a systematic review. Neuroscience & Biobehavioral Reviews, 55: 294-321.
  12. Dixon S.J. et al. (2012). Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell, 149(5): 1060-72.
  13. Froeliger B. et al. (2015). The effects of N-Acetylcysteine on frontostriatal resting-state functional connectivity, withdrawal symptoms and smoking abstinence: A double-blind, placebocontrolled fMRI pilot study. Drug Alcohol Depend, 156: 234-242.
  14. Gipson C.D. et al. (2021). Interactions of neuroimmune signaling and glutamate plasticity in addiction. Journal of Neuroinflammation, 18(1): 56.
  15. Goldstein R.Z., & Volkow N.D. (2011). Dysfunction of the prefrontal cortex in addiction: neuroimaging findings and clinical implications. Nature Reviews Neuroscience, 12(11): 652-69.
  16. Grant J.E., Kim S.W., & Odlaug B.L. (2007). N-acetyl cysteine, a glutamate-modulating agent, in the treatment of pathological gambling: a pilot study. Biological Psychiatry, 62(6): 652-7.
  17. Guo M.L. et al. (2023). Microglia NLRP3 inflammasome and neuroimmune signaling in substance use disorders. Biomolecules, 13(6): 922.
  18. Heilig M., Egli M., Crabbe J.C., & Becker. C. (2010). Acute withdrawal, protracted abstinence and negative affect in alcoholism: Are they linked?. Addiction Biology, 15(2): 169-84.
  19. Hofford R.S., Russo S.J., & Kiraly D.D. (2019). Neuroimmune mechanisms of psychostimulant and opioid use disorders. The European Journal of Neuroscience, 50(3): 2562-2573.
  20. Kalivas P.W. (2009). The glutamate homeostasis hypothesis of addiction. Nature Reviews Neuroscience, 10(8): 561-572.
  21. Koob G.F., & Schulkin J. (2019). Addiction and stress: An allostatic view. Neuroscience & Biobehavioral Reviews, 106: 245-262.
  22. LaRowe S.D. et al. (2007). Safety and tolerability of N-acetylcysteine in cocaine-dependent individuals. Am J Addict, 15(1): 105-110.
  23. LaRowe S.D. et al. (2013). A double-blind placebo-controlled trial of N-acetylcysteine in the treatment of cocaine dependence. The American Journal on Addictions, 22(5): 443-452.
  24. Minarini A. et al. (2017). N-acetylcysteine in the treatment of psychiatric disorders: current status and future prospects. Expert Opinion on Drug Metabolism & Toxicology, 13(3): 279-292.
  25. Moussawi K. et al. (2009). N-Acetylcysteine reverses cocaineinduced metaplasticity. Nature Neuroscience, 12(10): 182-189.
  26. Murnane K. ., Edinoff A.N., Cornett E.M., & Kaye A.D. (2023). Updated perspectives on the neurobiology of substance use disorders using neuroimaging. Substance Abuse and Rehabilitation, 14: 99-111.
  27. Murray J.E., & Lacoste J. (2012). N-Acetylcysteine as a Treatment for Addiction. In: Belin D. (Ed.). Addictions - From Pathophysiology to Treatment (pp. 355-380). IntechOpen.
  28. Packer L., Witt E.H., & Tritschler H.J. (1995). Alpha-lipoic acid as a biological antioxidant. Free Radical Biology and Medicine, 19(2): 227-250.
  29. Ren J.X. et al. (2020). Ferroptosis in neurological diseases. Frontiers in Cellular Neuroscience, 14: 218.
  30. Schmaal L. et al. (2012). N-acetylcysteine normalizes glutamate levels in cocaine-dependent patients: a randomized crossover magnetic
  31. resonance spectroscopy study. Neuropsychopharmacology, 37(9): 2143-2152.
  32. Scofi eld M.D., & Kalivas P.W. (2014). Astrocytic dysfunction and addiction: consequences of impaired glutamate homeostasis. Neurochemical Research, 20(6): 610-622.
  33. Seco M.J. et al. (2026). Neuroprogression in substance use disorders: Integrating molecular mechanisms, brain circuitry, biomarkers, and implications for clinical staging and service design. Int Rev Psychiatry. 7: 1-14.
  34. Sekine Y. et al. (2008). Methamphetamine causes microglial activation in the brains of human abusers. The Journal of Neuroscience, 28(22): 5756-5761.
  35. Shay K.P. et al. (2009). Alpha-lipoic acid as a dietary supplement: Molecular mechanisms and therapeutic potential. Biochimica et Biophysica Acta, 1790(10): 1149-1160.
  36. Shirpoor et al. (2008). Alpha-lipoic acid decreases DNA damage and oxidative stress induced by alcohol in the developing hippocampus
  37. and cerebellum of rat. Cell Physiol Biochem, 22(5-6): 769-76.
  38. Tomko R.L. et al. (2018). N-acetylcysteine: A potential treatment for substance use disorders. Current Psychiatry Reports, 20(6), 42.
  39. Viola T. et al. (2023). Effects of substance use disorder on oxidative and antioxidative stress markers: A systematic review and metaanalysis. Addiction Biology, 28(1), e13254.
  40. Volkow N.D., Wise R.A., & Baler R. (2017). The dopamine motive system: implications for drug and food addiction. Nature Reviews Neuroscience, 18(12): 741-752.
  41. Zhang W.J. et al. (2007). Alpha-lipoic acid attenuates LPS-induced inflammatory responses by activating the phosphoinositide 3-kinase/Akt signaling pathway. Proceedings of the National Academy of Sciences, 104(10): 4077-4082.

Metriche

Caricamento metriche ...